Also known as Symlin
Pramlintide (Symlin) is a relatively new adjunct for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of Bristol Myers-Squibb). Pramlintide is delivered as an acetate salt.Source: Wikipedia
Estimated Total Cost: $472.24 for an average of 28 days supply
Patients are most commonly prescribed pramlintide to treat diabetes, hyperlipidemia, hypothyroidism, and rabies.